A Big Study Found that Semaglutide Users Saw Increased Health Spending. Should We Be Surprised?
Shares:
This week is going to be a bit zany with travel. That’s going to wreak havoc on the Cost Curve publishing timetable. Please bear with me, because I suspect there
Lord, this is lousy. The New York Times is out with an explainer on why the United States has high drug prices. To the extent that there are myths around
One of the most important needs in the biopharma industry is communicators who can make the case not only for innovation but also for the broader policy and business environment